Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Kg

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Gmbh

Boehringer Ingelheim International Pharma Gmbh & Co. Kg

Birgit Jung

Horst Dollinger

Frank Himmelsbach

Gerd Schnorrenberg

Georg Speck

Franz Esser

Flavio Solca

Elke Langkopf

Peter Nickolaus

Hans Briem

Rolf Goeggel

Stefan Matthias Blech

Domnic Martyres

Christoph Hoenke

Pascale Pouzet

Juergen Mack

Erich Burger

Anke Baum

Kurt Schromm

Ralf Lotz

Ralf Anderskewitz

Holger Wagner

Dennis Fiegen

Thomas Fox

Thomas Metz

Joerg Kley

Rainer Walter

Michel Pairet

Christopher John Montague Meade

Peter Seither

Sven Luettke

Norbert Kraut

Andreas Weith

Norbert Hauel

Henri Doods

Georg Dahmann

Matthias Hoffmann

Richard Reichl

Michael Paul Pieper

Raimund Kuelzer

Angelo Ceci

Franz Birke

Hans Michael Jennewein

Markus Ostermeier

Rainer Soyka

Karl-Heinz Heider

Christel Schmelzer

Andreas Zophel

Hartmut Beug

Renate Konopitzky

Christopher John Meade

Barbara Kistler

Ulrike Kuefner-Muehl

Horst Johann Ahorn

Gerd Schorrenberg

Christopher J Montague Meade

Jurgen Mack

Thomas Waerner

Martin Jechlinger

Ido M Tamir

Stefan Gruenert

Karsten Quast

Stefan Mueller

G&uuml;nther Giesler

Hans-Peter Ignatow

Stefan Blech

Heteroaryloxy-substituted benzoic acid amides of general formula I wherein the groups Rto Ras well as X and Y are defined according to claim, including the tautomers, the stereoisomers, the mixtures and the salts thereof. The compounds according to the invention are suitable for the treatment of respiratory complaints, particularly COPD and asthma.

Benzamides, production thereof, and use thereof as medicaments

Disubstituted tetrahydrofuranyl compounds of general formula I of which the following are exemplary: 

Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists

The invention relates to new pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system and cancers. This invention also relates to pharmaceutical compositions containing these compounds.

Substituted pteridines

The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO, but preferably SO, and wherein R, Rand Rhave the meanings given in the description,and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases

The present invention relates to spirocyclic heterocycles of general formula (I) the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways, and the preparation thereof.

Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production

The present invention relates to bicyclic heterocycles of general formula wherein

Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

The present invention provides compounds according to general formula (I) which are proposed for the treatment of respiratory complaints, particularly asthma and COPD.

7-(piperazine-1-ymethyl)-1H-indole-2-carboxylic acid (phenyl)-amide derivatives and allied compounds as p38 MAP kinase inhibitors for the treatment of respiratory diseases

The present invention relates to cyclohexyloxy-substituted heterocycles of general formula (I) the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways and the preparation thereof.

Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them

The present invention relates to the use of quinazoline derivatives, which show EGFR inhibitory activity, for the prevention and/or treatment of virus-induced diseases, preferably virus induced respiratory diseases and exacerbation in chronic airway diseases such as COPD or asthma.

Use of quinazoline derivatives for the treatment of viral diseases

The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO, but preferably SO, and wherein R, Rand Rhave the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

Dihydrothienopyrimidines for the treatment of inflammatory diseases

Quinazoline derivatives and pharmaceutical compositions containing them

The present invention relates to bicyclic heterocycles of general formula the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, as well as benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.

Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same

Dihydrothienopyrimidines of formula 1 and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

Compounds for the treatment of inflammatory diseases

Growing community of inventors

Laupheim, Germany

Birgit Jung